Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
University of California Los Angeles, Los Angeles, California Australia
Chris OBrien Lifehouse, Camperdown, New South Wales Peter MacCallum Cancer Centre, Melbourne, Victoria